Bayer receives approval of new treatment regimen for Eylea ® in the EU (for specialized target groups only)

New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news